Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

U.K. Government funding for phase III trial of PRO-2000

April 11, 2005

Takara Bio and MolMed sign AIDS gene therapy development agreement

April 11, 2005

Gilead Sciences' JTK-303 license agreement gets FTC clearance

April 11, 2005

Theratechnologies plans phase III trials for ThGRF

April 5, 2005

Dosing begins in phase I study of CCR5 mAb in HIV patients

April 5, 2005

Completion of enrollment for phase I HIV vaccine trial

March 29, 2005

Gilead signs JTK-303 licensing agreement

March 24, 2005

TAK-220 chosen as a clinical candidate for HIV-1 treatment

March 21, 2005

Efficacy of MIV-310 in phase II HIV trial does not warrant further development

March 18, 2005

Update on the therapeutic benefits of Remune(R) in HIV infection

March 17, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...